Schieber et al. demonstrate that a specific gut microbiota bacterial strain induces a host-mediated protection mechanism against inflammation-driven wasting syndrome. This salutary effect confers a net survival advantage against bacterial infection, without interfering with the host's pathogen load, revealing that host-microbiota interactions regulate disease tolerance to infection.
Immune-driven resistance mechanisms are usually perceived as the central defense strategy preventing the pathological outcome of infections. We now realize, however, that additional defense strategies are required to achieve this goal (Medzhitov et al., 2012) . These include an evolutionary conserved defense strategy known as disease tolerance, which preserves host homeostasis during infection without interfering with the host's pathogen load (Medzhitov et al., 2012) . The study by Schieber et al. (2015) published in Science highlights how host/microbiota interactions manipulate this defense strategy to confer host protection against bacterial infections and ultimately preserve homeostasis.
There is now a growing body of experimental evidence to suggest that tissue damage control mechanisms (Soares et al., 2014 ) play a central role in sustaining disease tolerance to viral (Rodrigue-Gervais et al., 2014) , bacterial (Larsen et al., 2010) , or protozoan (Ferreira et al., 2011; Rå berg et al., 2007) infections. While host microbiota/interactions are known to regulate immune-driven resistance mechanisms against viral (Ichinohe et al., 2011) , bacterial (Cash et al., 2006) , or protozoan infections (Yilmaz et al., 2014) , whether this was also the case for tissue damage control mechanisms regulating disease tolerance to these infections remained unknown. Schieber et al. (2015) demonstrate that a specific bacterial member of the gut microbiota, namely Escherichia coli (E. coli) O21:H + , confers a strong survival advantage against enteric and lung bacterial infections in mice. This occurs without interfering with pathogen growth (i.e., host pathogen load), revealing that E. coli O21:H + confers disease tolerance to bacterial infections. The mechanism via which the protective effect of E. coli O21:H + is exerted involves sensing of this microbiota component by a host inflammasome signaling platform containing the NOD-like receptor (NLR) family CARD domain-containing protein 4 (Nlrc4) (Figure 1 ). While engagement of the Nlrc4 inflammasome was well known to trigger the cleavage and secretion of interleukin (IL)-18 and IL-1b, the authors now show that IL-18 and, to a lesser extent, IL-1b are critical to maintain systemic levels of insulin-like growth factor-1 (IGF-1) during bacterial infections. This is required to activate a downstream signal transduction pathway in muscle cells, involving the Phosphoinositide 3-kinase (PI3K)/Akt and antagonizing muscle wasting via a process that represses the expression of the E3 ubiquitin ligases Atrogin-1 and Murf1 (Figure 1 ). This tissue damage control mechanism prevents the development of wasting syndrome and accounts for the survival advantage conferred by E. coli O21:H + against bacterial infections (Figure 1) . Surprisingly, the protective effect exerted by E. coli O21:H + requires its active translocation from the gut into white adipose tissue. The mechanism via which translocates across the gut epithelial barrier and accumulates specifically in white adipose tissue. This occurs via an unknown mechanism that does not require disruption of the intestinal barrier. Once in white adipose tissue, E. coli O21:H + is sensed by the Nlrc4 inflammasome (presumably expressed in resident macrophages; Mø?). This triggers the production of IL-1b and IL-18, possibly acting synergistically to induce IGF-1 production in white adipose tissue and sustain systemic levels of IGF-1 during bacterial infections. IGF-1 signaling via PI3K/Akt activation in muscle cells prevents the upregulation of atrophy associated programs involving the muscle-specific E3 ubiquitin ligases Murf1 and Atrogin1 and leading to muscle wasting. This tissue damage control mechanism confers disease tolerance to bacterial infections. this occurs is not yet established but is shown to act independently of the host Nlrc4 inflammasome. As a final note, the study by Schieber et al. (2015) suggests that manipulation of the IGF-1/PI3K/Akt/ Atrogin-1;Murf1 signaling transduction pathway may be a valuable therapeutic approach to induce tissue damage control and to confer disease tolerance to bacterial infections. This should be particularly relevant to the treatment of severe sepsis, given the relative contribution of muscle wasting to the overall morbidity and mortality of this infectious disease. 294709-DAMAGECONTROL.
